JAMA Oncology Author Interviews podcast

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

0:00
15:06
Spol 15 sekunder tilbage
Spol 15 sekunder frem

Flere episoder fra "JAMA Oncology Author Interviews"